Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Tango Therapeutics, Inc.
Novartis
M.D. Anderson Cancer Center
Kivu Bioscience Inc.
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Tango Therapeutics, Inc.
Instituto do Cancer do Estado de São Paulo
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Bayer
National Cancer Institute (NCI)
Turning Point Therapeutics, Inc.
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
Eastern Cooperative Oncology Group
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
Hoffmann-La Roche
Institut Bergonié
City of Hope Medical Center
University of California, Irvine
M.D. Anderson Cancer Center
ViroMissile, Inc.
Dana-Farber Cancer Institute
Kaiser Permanente
University of Florida
Essen Biotech
MacroGenics
Indiana University
City of Hope Medical Center
Duke University
Fred Hutchinson Cancer Center
Perspective Therapeutics
M.D. Anderson Cancer Center
Ocellaris Pharma, Inc.
Eli Lilly and Company
Var2 Pharmaceuticals
M.D. Anderson Cancer Center
UNICANCER
Mayo Clinic
Tanabe Pharma America, Inc.